# Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer

> **NCT00853125** · PHASE2 · TERMINATED · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 10 (actual)

## Conditions studied

- Kidney Cancer

## Interventions

- **BIOLOGICAL:** therapeutic allogeneic lymphocytes
- **DRUG:** sunitinib malate

## Key facts

- **NCT ID:** NCT00853125
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-02
- **Primary completion:** 2014-02-22
- **Final completion:** 2014-02-22
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2021-04-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00853125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00853125, "Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00853125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*